Expert Panel Discussion: To Degrade or Not to Degrade – Rationale Behind Selecting Inhibitory or Degradation Modality

Time: 3:00 pm
day: Day One


  • Highlighting the advantages of using a degrader vs. catalytic site inhibitors and optimizing PKPD
  • Optimizing the linker, linage and E3 ligand for maximal binding and optimizing residency time
  • Discussing the issues of translating degradation efficiency to the clinic with different kinase inhibitors